Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250236175> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4250236175 abstract "Background: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registries have been established in both Finland and Sweden. Our study explored potential differences in the care of IPF in these two countries.
 Methods: Patients included consecutively in the Finnish and Swedish IPF-registries from January 1, 2014 through December 31, 2016 were included in the study. Data on demographics and lung function at the time of inclusion were collected. Access to antifibrotic drugs and data on disease outcomes, mortality and the proportion of patients who underwent lung transplantation, was collected during a 3-year follow up.
 Results: One-hundred and fifty-two patients from the Finnish and 160 patients from the Swedish IPF-cohorts were included in the study. At inclusion, Finnish patients were significantly older than the Swedish patients (74.6 years vs 72.5 years, p = 0.017). The proportion of non-smokers was significantly higher in the Finnish cohort (41.7% vs 26.9%, p = 0.007). Forced vital capacity (FVC), % of predicted (78.2 vs 71.7 for Finnish and Swedish patients, respectively, p = 0.01) and diffusion capacity for carbon monoxide (DLCO), % of predicted (53.3 vs 48.2 for Finnish and Swedish patients, respectively, p = 0.002) were significantly higher in the Finnish cohort compared to the Swedish cohort at the time of inclusion. During the 3-year follow up period, 45 (29.6%) Finnish and 111 (69.4%) Swedish patients, respectively, were initiated on treatment with an antifibrotic drug (pirfenidone or nintedanib) (p < 0.001). When comparing possible determinants of treatment, patients with higher FVC % were less likely to start antifibrotic drugs (OR 0.96, 95%CI 0.93–1.00, p < 0.024). To be resident in Sweden was the main determinant for receiving antifibrotic drugs (OR 5.48, 95%CI 2.65–11.33, p < 0.0001). No significant difference in number of deaths and lung transplantation during the follow up period was found.
 Conclusions: This study highlights differences concerning how IPF patients are treated in Finland and Sweden. How these differences will influence the long-term outcome of these patients is unknown." @default.
- W4250236175 created "2022-05-12" @default.
- W4250236175 creator A5018872682 @default.
- W4250236175 creator A5030092837 @default.
- W4250236175 creator A5042794963 @default.
- W4250236175 creator A5055856879 @default.
- W4250236175 creator A5057667043 @default.
- W4250236175 creator A5069835383 @default.
- W4250236175 creator A5087519704 @default.
- W4250236175 date "2019-12-11" @default.
- W4250236175 modified "2023-09-30" @default.
- W4250236175 title "Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries" @default.
- W4250236175 doi "https://doi.org/10.4081/mrm.2018.140" @default.
- W4250236175 hasPublicationYear "2019" @default.
- W4250236175 type Work @default.
- W4250236175 citedByCount "0" @default.
- W4250236175 crossrefType "journal-article" @default.
- W4250236175 hasAuthorship W4250236175A5018872682 @default.
- W4250236175 hasAuthorship W4250236175A5030092837 @default.
- W4250236175 hasAuthorship W4250236175A5042794963 @default.
- W4250236175 hasAuthorship W4250236175A5055856879 @default.
- W4250236175 hasAuthorship W4250236175A5057667043 @default.
- W4250236175 hasAuthorship W4250236175A5069835383 @default.
- W4250236175 hasAuthorship W4250236175A5087519704 @default.
- W4250236175 hasBestOaLocation W42502361751 @default.
- W4250236175 hasConcept C126322002 @default.
- W4250236175 hasConcept C16020263 @default.
- W4250236175 hasConcept C165637977 @default.
- W4250236175 hasConcept C187212893 @default.
- W4250236175 hasConcept C201903717 @default.
- W4250236175 hasConcept C2777714996 @default.
- W4250236175 hasConcept C2778341716 @default.
- W4250236175 hasConcept C2779832356 @default.
- W4250236175 hasConcept C2780171596 @default.
- W4250236175 hasConcept C2781448352 @default.
- W4250236175 hasConcept C3018587741 @default.
- W4250236175 hasConcept C55520419 @default.
- W4250236175 hasConcept C71924100 @default.
- W4250236175 hasConcept C72563966 @default.
- W4250236175 hasConcept C75603125 @default.
- W4250236175 hasConceptScore W4250236175C126322002 @default.
- W4250236175 hasConceptScore W4250236175C16020263 @default.
- W4250236175 hasConceptScore W4250236175C165637977 @default.
- W4250236175 hasConceptScore W4250236175C187212893 @default.
- W4250236175 hasConceptScore W4250236175C201903717 @default.
- W4250236175 hasConceptScore W4250236175C2777714996 @default.
- W4250236175 hasConceptScore W4250236175C2778341716 @default.
- W4250236175 hasConceptScore W4250236175C2779832356 @default.
- W4250236175 hasConceptScore W4250236175C2780171596 @default.
- W4250236175 hasConceptScore W4250236175C2781448352 @default.
- W4250236175 hasConceptScore W4250236175C3018587741 @default.
- W4250236175 hasConceptScore W4250236175C55520419 @default.
- W4250236175 hasConceptScore W4250236175C71924100 @default.
- W4250236175 hasConceptScore W4250236175C72563966 @default.
- W4250236175 hasConceptScore W4250236175C75603125 @default.
- W4250236175 hasLocation W42502361751 @default.
- W4250236175 hasLocation W42502361752 @default.
- W4250236175 hasLocation W42502361753 @default.
- W4250236175 hasLocation W42502361754 @default.
- W4250236175 hasLocation W42502361755 @default.
- W4250236175 hasLocation W42502361756 @default.
- W4250236175 hasLocation W42502361757 @default.
- W4250236175 hasOpenAccess W4250236175 @default.
- W4250236175 hasPrimaryLocation W42502361751 @default.
- W4250236175 hasRelatedWork W2051083934 @default.
- W4250236175 hasRelatedWork W2555155415 @default.
- W4250236175 hasRelatedWork W2556745572 @default.
- W4250236175 hasRelatedWork W2806388389 @default.
- W4250236175 hasRelatedWork W2906041115 @default.
- W4250236175 hasRelatedWork W2980575734 @default.
- W4250236175 hasRelatedWork W2986781304 @default.
- W4250236175 hasRelatedWork W3087338830 @default.
- W4250236175 hasRelatedWork W3093425191 @default.
- W4250236175 hasRelatedWork W4250236175 @default.
- W4250236175 hasVolume "13" @default.
- W4250236175 isParatext "false" @default.
- W4250236175 isRetracted "false" @default.
- W4250236175 workType "article" @default.